Buyback Approval and Plan - The board of directors approved a share buyback plan using self-owned funds through centralized bidding on January 23, 2024, with a total fund amount between 200 million yuan and 400 million yuan, and a maximum buyback price of 7 yuan per share [1] Buyback Implementation - The company initiated its first share buyback on January 29, 2024, and completed the buyback by July 21, 2024, acquiring 63.579048 million shares, which is 2.47% of the total share capital at that time. The highest buyback price was 5.00 yuan per share, the lowest was 4.08 yuan, and the average price was 4.72 yuan, with a total expenditure of approximately 299.9241 million yuan [2][3] Use of Funds and Impact - The funds used for the buyback were from the company's own resources and did not significantly impact its daily operations, financial status, or future development. The buyback did not alter the company's control or affect its listing status [3] Shareholder Trading Activity - During the buyback period, company directors, supervisors, and senior management did not trade company shares, except for the controlling shareholder, Zhejiang Pharmaceutical Health Industry Group, which planned to increase its stake by 2% to 4% of the total share capital [3] Change in Buyback Share Purpose - The purpose of the repurchased shares was changed from "for equity incentives" to "for cancellation to reduce registered capital" as approved in board meetings held on April 23 and May 2025 [3] Cancellation of Repurchased Shares - The company announced a notification to creditors regarding the cancellation of repurchased shares, with a creditor declaration period from May 24 to July 7, 2025. No creditors requested early debt repayment or guarantees during this period [5] Post-Cancellation Share Capital Changes - After the cancellation of shares, the total share capital will decrease from 2,585,167,996 shares to 2,521,588,948 shares, reflecting a change in ownership percentages among shareholders [6] Shareholder Ownership Changes - Following the cancellation, the controlling shareholder, Zhejiang Pharmaceutical Health Industry Group, maintained its shareholding at 594,209,740 shares, increasing its ownership percentage from 22.99% to 23.56% [6]

年第二次临时股东会议案之一 关于变更回购股份用途并注销暨减少注册资本的议案 各位股东及授权代表： 根据《上海证券交易所上市公司自律监管指引第 7 号—回购股 份》等相关规定，公司拟将 2022 年回购股份用途由"采用集中竞价 交易方式出售"变更为"用于注销并减少公司注册资本"，公司 2022 年已回购股份中尚未出售的 5,007,526 股股份将被注销，并减少公司 注册资本，具体情况如下： 深圳市金证科技股份有限公司 2025 三、本次注销已回购股份对公司的影响 本次变更回购股份用途后，公司 2022 年已回购股份中尚未出售 的 5,007,526 股股份将被注销，公司总股本将由 946,275,005 股减少 至 941,267,479 股 ， 公 司 注 册 资 本 将 由 946,275,005 元 减 少 至 本次变更回购股份用途并注销事项符合《上市公司股份回购规 则》《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等 相关规定，不会对公司的财务状况和经营成果产生重大影响，亦不会 对公司的债务履行能力、持续经营能力及股东权益等产生重大影响， 不存在损害公司及全体股东权益的情形，不会导致公司控 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 2、公司已于2025年6月4日在中国证券登记结算有限责任公司深圳分公司办理完毕上述回购股份的注销 手续。 航锦科技股份有限公司（以下简称"公司"）于2024年2月7日召开第九届董事会第7次临时会议，于2024 年2月23日召开2024年第一次临时股东大会审议通过了《关于回购公司股份方案的议案》，同意公司以 自有或自筹资金以集中竞价交易方式回购公司部分已发行的人民币普通股（A股）股票，用于实施员工 持股计划或股权激励。本次回购资金总额不低于人民币30,000万元（含）且不超过人民币40,000万元 （含），回购价格不超过37.95元/股（含）（经调整）。实施期限为自公司股东大会审议通过回购方案 之日起12个月内。公司于2024年8月28日召开第九届董事会第10次临时会议，审议通过了《关于变更回 购股份用途并注销的议案》，同意公司将原回购股份方案中的回购股份用途由"用于实施员工持股计划 或股权激励"变更为"用于注销并减少公司注册资本"，并经公司2024年第三次临时股东大会审议通过。 具体内容详见公司分别于2024年2月8日、2024年8月29日在巨潮资讯网（htt ...

证券代码：601567 证券简称：三星医疗 公告编号：临 2025-043 宁波三星医疗电气股份有限公司 关于变更回购股份用途并注销的公告 本公司董事会及全体董事保证公告内容不存在虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 变更回购股份用途及数量：公司拟将回购专用证券账户中 5,755,371 股回 购股份的用途由"用于实施员工持股计划或股权激励计划"变更为"用于注销并 减少公司注册资本"。 ? 本次拟变更用途并注销的股份共计 5,755,371 股，占公司当前总股本的比 例约为 0.41%。前述股份注销完成后，公司总股本预计将由 1,411,006,571 股变更 为 1,405,251,200 股，注册资本预计将由 1,411,006,571 元变更为 1,405,251,200 元。 ? 本次变更回购股份用途并注销事项尚需提交公司股东会审议通过后实施。 宁波三星医疗电气股份有限公司（以下简称"公司"）于 2025 年 5 月 28 日召开第六届董事会第二十三次会议，审议通过了《关于变更部分回购股份用途 为注销并减少公司注册资本的议案》。公司拟 ...

Core Viewpoint - The company, Dazong Laser Technology Industry Group Co., Ltd., plans to change the purpose of its repurchased shares from employee stock ownership plans and maintaining shareholder value to cancellation for reducing registered capital [1][2]. Summary by Sections 1. Basic Information on Share Repurchase - The company approved a share repurchase plan on February 2, 2024, with a budget of between RMB 500 million and RMB 1 billion, at a price not exceeding RMB 25 per share [1]. - A total of 22,589,592 shares were repurchased, accounting for 2.15% of the total share capital, with the highest transaction price at RMB 24.96 and the lowest at RMB 15.41 [2]. 2. Reasons for Changing the Purpose of Share Repurchase - The decision aligns with regulatory guidelines encouraging companies to cancel repurchased shares to protect investor interests and enhance long-term investment value [2][3]. - The change is based on the company's operational status and strategic planning, aiming to improve per-share equity and boost investor confidence [2]. 3. Impact of the Change on Company Shares - Following the cancellation, the total share capital will decrease from 1,052,193,000 shares to 1,029,603,408 shares [2]. - The share structure will adjust, with limited sale condition shares remaining at 72,876,026 (7.08%) and unrestricted shares decreasing to 956,727,382 (92.92%) [2]. 4. Procedures for Implementing the Change - The change requires approval from the shareholders' meeting and must comply with relevant legal and regulatory procedures [3]. - The board will seek authorization from shareholders to proceed with the cancellation and necessary registrations [3].